Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Journal of Ovarian Research
Published in: Journal of Ovarian Research 1/2019

Open Access 01-12-2019 | Ovarian Cancer | Review

Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review

Authors: Sander Dumont, Ziga Jan, Ruben Heremans, Toon Van Gorp, Ignace Vergote, Dirk Timmerman

Published in: Journal of Ovarian Research | Issue 1/2019

Login to get access

Abstract

Epithelial ovarian cancer (EOC) remains the most lethal gynecological cancer in developed countries, indicating the need for further research. Although current cancer models prove useful, they have major limitations. Organoids, a novel in vitro 3D cell culture technique, derived from stem cells, could provide a bridge between the current preclinical platforms. However, this technique is still in its early stages. After conducting a systematic literature search, only sixteen manuscripts concerning ovarian related organoids could be retrieved.
In this review, we discuss current tumor models, including organoids and provide a comprehensive review about organoids of ovarian tissue. Potential future applications are addressed, proving organoids to be an interesting platform for modeling tumorigenesis, drug testing and screening and other applications. Recent advancements could usher in a new era of highly personalized medicine in EOC.
Appendix
Available only for authorised users
Literature
1.
Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018;103:356–87.CrossRef
2.
Jabs J, Zickgraf FM, Park J, Wagner S, Jiang X, Jechow K, et al. Screening drug effects in patient-derived cancer cells links organoid responses to genome alterations. Mol Syst Biol. 2017;13:955.CrossRef
3.
Phan N, Huang J, Eisenberg D, Memarzadeh S, Soragni A. Abstract 5782: a novel method for high-throughput drug screening in 3D tumor organoids. Cancer Res. 2017;77(13 Supplement):5782.
4.
Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ, et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian cancer organoids. Cancer Discov. 2018;8:1404–21.CrossRef
5.
Swan HA, Rosati R, Bridgwater C, Churchill MJ, Watt RM, Shaw RC, et al. Abstract 1619: personalized medicine: a CLIA-certified high-throughput drug screening platform for ovarian cancer. Cancer Res. 2018;78(13 Supplement):1619.
6.
Kopper O, de Witte CJ, Lõhmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25:838–49.CrossRef
7.
Phan N, Hong JJ, Tofig B, Mapua M, Elashoff D, Moatamed NA, et al. A simple high-throughput approach identifies actionable drug sensitivities in patient-derived tumor organoids. Commun Biol. 2019;2:78.CrossRef
8.
Maru Y, Tanaka N, Itami M, Hippo Y. Efficient use of patient-derived organoids as a preclinical model for gynecologic tumors. Gynecol Oncol. 2019;154:189–98.CrossRef
9.
Gotimer K, Chen H, Leiserowitz GS, Smith LH. Short-term organoid culture for drug sensitivity testing in high-grade serous ovarian cancer. Gynecol Oncol. 2019;153:e13.CrossRef
10.
Hill SJ, Lizotte P, Horowitz NS, Muto MG, Worley MJ, Feltmate CM, et al. Abstract 368A: functional assessment of DNA damage repair defects and the anti-tumor immune response in high grade serous ovarian cancers using patient-derived organoids. Cancer Res. 2019;79(13):Supplement:368A.
11.
Sachs N, Clevers H. Organoid cultures for the analysis of cancer phenotypes. Curr Opin Genet Dev. 2014;24:68–73.CrossRef
12.
Aboulkheyr Es H, Montazeri L, Aref AR, Vosough M, Baharvand H. Personalized cancer medicine: an organoid approach. Trends Biotechnol. 2018;36:358–71.CrossRef
13.
Drost J, Clevers H. Organoids in cancer research. Nat Rev Cancer. 2018;18:407–18.CrossRef
14.
Weiswald L-B, Bellet D, Dangles-Marie V. Spherical cancer models in tumor biology. Neoplasia. 2015;17:1–15.CrossRef
15.
Clevers H. Modeling development and disease with organoids. Cell. 2016;165:1586–97.CrossRef
16.
Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459:262–5.CrossRef
17.
Kretzschmar K, Clevers H. Organoids: modeling development and the stem cell niche in a dish. Dev Cell. 2016;38:590–600.CrossRef
18.
Fatehullah A, Tan SH, Barker N. Organoids as an in vitro model of human development and disease. Nat Cell Biol. 2016;18:246–54.CrossRef
19.
Drost J, Clevers H. Translational applications of adult stem cell-derived organoids. Development. 2017;144:968–75.CrossRef
20.
Bartfeld S, Clevers H. Stem cell-derived organoids and their application for medical research and patient treatment. J Mol Med. 2017;95:729–38.CrossRef
21.
Kwong J, Chan FL, Wong K, Birrer MJ, Archibald KM, Balkwill FR, et al. Inflammatory cytokine tumor necrosis factor α confers precancerous phenotype in an organoid model of normal human ovarian surface epithelial cells. Neoplasia. 2009;11:529–41.CrossRef
22.
Weeber F, Ooft SN, Dijkstra KK, Voest EE. Tumor organoids as a pre-clinical cancer model for drug discovery. Cell Chem Biol. 2017;24:1092–100.CrossRef
23.
Picollet-D’hahan N, Dolega ME, Freida D, Martin DK, Gidrol X. Deciphering cell intrinsic properties: a key issue for robust organoid production. Trends Biotechnol. 2017;35:1035–48.CrossRef
24.
Nie J, Hashino E. Organoid technologies meet genome engineering. EMBO Rep. 2017;18:367–76.CrossRef
25.
Driehuis E, Clevers H. CRISPR/Cas 9 genome editing and its applications in organoids. Am J Physiol Gastrointest Liver Physiol. 2017;312:G257–65.CrossRef
26.
Xu H, Jiao Y, Qin S, Zhao W, Chu Q, Wu K. Organoid technology in disease modelling, drug development, personalized treatment and regeneration medicine. Exp Hematol Oncol. 2018;7:30.CrossRef
27.
Neal JT, Kuo CJ. Organoids as models for neoplastic transformation. Annu Rev Pathol Mech Dis. 2016;11:199–220.CrossRef
28.
Mebarki M, Bennaceur A, Bonhomme-Faivre L. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology. Drug Discov Today. 2018;23:857–63.CrossRef
29.
Rossi G, Manfrin A, Lutolf MP. Progress and potential in organoid research. Nat Rev Genet. 2018;19:671–87.CrossRef
30.
Roelofs C, Hollande F, Redvers R, Anderson RL, Merino D. Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer. Biochem Soc Trans. 2019;47:109–17.CrossRef
31.
Jackson EL, Lu H. Three-dimensional models for studying development and disease: moving on from organisms to organs-on-a-chip and organoids. Integr Biol. 2016;8:672–83.CrossRef
32.
Seino T, Kawasaki S, Shimokawa M, Tamagawa H, Toshimitsu K, Fujii M, et al. Human pancreatic tumor organoids reveal loss of stem cell niche factor dependence during disease progression. Cell Stem Cell. 2018;22:454–67 e6.CrossRef
33.
Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23:393–410.CrossRef
34.
Yucer N, Holzapfel M, Jenkins Vogel T, Lenaeus L, Ornelas L, Laury A, et al. Directed differentiation of human induced pluripotent stem cells into fallopian tube epithelium. Sci Rep. 2017;7:10741.CrossRef
35.
Ng A, Barker N. Ovary and fimbrial stem cells: biology, niche and cancer origins. Nat Rev Mol Cell Biol. 2015;16:625–38.CrossRef
36.
Kessler M, Hoffmann K, Brinkmann V, Thieck O, Jackisch S, Toelle B, et al. The notch and Wnt pathways regulate stemness and differentiation in human fallopian tube organoids. Nat Commun. 2015;6:8989.CrossRef
37.
Xie Y, Park ES, Xiang D, Li Z. Long-term organoid culture reveals enrichment of organoid-forming epithelial cells in the fimbrial portion of mouse fallopian tube. Stem Cell Res. 2018;32:51–60.CrossRef
38.
Bell D, Berchuck A, Birrer M, Chien J, Cramer DW, Dao F, et al. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609–15.CrossRef
39.
Chen EY, Mehra K, Mehrad M, Ning G, Miron A, Mutter GL, et al. Secretory cell outgrowth, PAX2 and serous carcinogenesis in the fallopian tube. J Pathol. 2010;222:110–6.CrossRef
40.
King SM, Modi DA, Eddie SL, Burdette JE. Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through upregulation of the PI3-kinase pathway. J Ovarian Res. 2013;6:12.CrossRef
41.
Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. Nat Rev Dis Primers. 2016;2:16061.CrossRef
Metadata
Title
Organoids of epithelial ovarian cancer as an emerging preclinical in vitro tool: a review
Authors
Sander Dumont
Ziga Jan
Ruben Heremans
Toon Van Gorp
Ignace Vergote
Dirk Timmerman
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Journal of Ovarian Research / Issue 1/2019
Electronic ISSN: 1757-2215
DOI
https://doi.org/10.1186/s13048-019-0577-2

Other articles of this Issue 1/2019

Journal of Ovarian Research 1/2019 Go to the issue

Research

Abnormal expression of HSP70 may contribute to PCOS pathology

Research

Development and validation of circulating CA125 prediction models in postmenopausal women

Research

The ovarian germinal reserve and apoptosis-related proteins in the infant and adolescent human ovary

Research

PD-L1 expression on stromal tumor-infiltrating lymphocytes is a favorable prognostic factor in ovarian serous carcinoma

Research

Association of the hypoxia-inducible factor-1α (HIF-1α) gene polymorphisms with prognosis in ovarian clear cell carcinoma

Research

Higher expression of calcineurin predicts poor prognosis in unique subtype of ovarian cancer